latest news releases from the newsroom
SVB Financial Group
SVB Financial Group Prices $200 Million of Its 3.875% Convertible Senior Notes
SANTA CLARA, Calif., April 2, 2008 (PRIME NEWSWIRE) -- SVB Financial Group (Nasdaq:SIVB) announced today that it has priced $200 million aggregate principal amount of 3.875% convertible senior notes due in 2011. The notes will be sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. SVB Financial Group also granted the initial purchaser of the notes the right to purchase up to an additional $50 million aggregate principal amount of notes solely to cover over-allotments. The sale is expected to close April 7, 2008, subject to customary closing conditions.
MediciNova to Present Additional Clinical Data Demonstrating Potential Neuroprotection Benefits of MN-166 in Multiple Sclerosis At the 18th Meeting of the European Neurological Society
SAN DIEGO, April 2, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it will present additional data from a double-blind analysis of the first year of treatment from its two-year Phase II clinical trial of MN-166, a novel, orally administered compound being evaluated for the treatment of multiple sclerosis (MS), at the 18th Meeting of the European Neurological Society to be held in Nice, France from June 7 to 11, 2008.